Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

AIM ImmunoTech Inc. Director's Dealing 2018

Nov 29, 2018

35334_dirs_2018-11-29_9ae1ba4e-e375-4f2b-823e-be06d59e93a3.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: HEMISPHERX BIOPHARMA INC (HEB)
CIK: 0000946644
Period of Report: 2018-11-27

Reporting Person: PASCALE ADAM (CFO)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2018-11-27 Common Stock A 2500 Acquired 62148 Direct

Footnotes

F1: The Board of Directors awarded 2,500 shares of Company common stock to each employee, executive, and board member as a holiday bonus to be issued after January 2, 2019.